AMNOG Insights

Current AMNOG procedures show which evidence supports the benefit assessment

The formal requirements for the German early benefit assessment are well established. Their implications for an individual medicine, however, become clear only within the specific assessment.

IQWiG assessments and G-BA decisions show which evidence is considered for specific patient populations, how the appropriate comparator therapy influences the assessment and which outcomes or analyses can support the determination of added benefit.

Differences between a clinical development programme and the requirements of the German benefit assessment can provide important insights for future procedures. The relevant question is therefore not only what the final assessment concludes, but how that conclusion was reached.

AMNOG Insights examines the practical implications for Market Access

The early benefit assessment does not stand in isolation at the end of clinical development. Decisions on study populations, comparators, outcomes and analyses made years before AMNOG dossier submission can determine which evidence is ultimately available for the German assessment.

Current procedures can therefore also be informative for other products and indications. They show where assessment standards are becoming more concrete, which methodological questions recur and which evidence strategies prove sufficiently robust under German requirements.

Changes in the regulatory and health policy environment add another dimension. New legislation, adjustments to procedural requirements and developments in access to health and real-world data can directly affect dossier strategy and Market Access planning.

JCA changes the interface between European evidence and AMNOG

EU HTA adds another layer to this environment. For medicines within the scope of Joint Clinical Assessment, clinical evidence is assessed at European level before feeding into subsequent national HTA processes.

The first procedures therefore also make the differences and connections between JCA and AMNOG more visible. Populations and comparators included in the European assessment scope may not fully correspond to the subsequent German assessment question. National requirements concerning outcomes, analyses and updated evidence also remain relevant.

For Market Access, this creates an additional planning question: How can evidence be prepared early enough to support both the European assessment and the subsequent requirements of the German benefit assessment? Experience from the first JCA and AMNOG procedures is beginning to provide concrete insights into this interface.

AMNOG Insights provides expert analysis of procedures and developments

AMNOG Insights analyses current benefit assessments, G-BA decisions, methodological questions and regulatory developments relevant to German Market Access.

The focus is not only on what has changed or how an individual procedure concluded. The key question is what these developments mean for evidence planning, dossier preparation and future AMNOG procedures.